Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
Surrozen is initially developing SZN-1326 for moderate to severe ulcerative colitis in inflammatory bowel disease.
- Surrozen is initially developing SZN-1326 for moderate to severe ulcerative colitis in inflammatory bowel disease.
- Following recent completion of IND-enabling GLP tox studies, Surrozen expects to initiate Phase 1 clinical trials of both SZN-1326 and SZN-043 in healthy volunteers in the third quarter of 2022.
- The data included results from multiple disease models and species and were presented through 26 posters and oral presentations at 5 major medical meetings in 2021.
- Financial Results for the Fourth Quarter Ended December 31, 2021
Cash Position: Cash, cash equivalents and marketable securities were $123.5 million as of December 31, 2021, compared to $135.4 million as of September 30, 2021.